BRAF and cancer: For stage I‐III cancer patients, either a RAS or BRAF mutation was detected in 24/56 (42.9%) of requested LPs, while LP was positive in 9/22 (40.9%) cases for stage I–II patients, and for 1/5 (20%) stage I cases.